Oncternal Therapeutics Ownership 2024 | Who Owns Oncternal Therapeutics Now?
Institutional Ownership
14.22%
Insider Ownership
9.23%
Retail Ownership
76.55%
Institutional Holders
37.00
Oncternal Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | - | - | - | -20,087 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -35 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -6,417 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -84,706 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -161,401 | -100.00% | - | Mar 31, 2024 |
| VANGUARD GROUP INC | - | - | - | -2,860,906 | -100.00% | - | Mar 31, 2024 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | - | - | - | -53,554 | -100.00% | - | Mar 31, 2024 |
| DELTA ASSET MANAGEMENT LLC/TN | - | - | - | -7 | -100.00% | - | Mar 31, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -32,249 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -92,980 | -100.00% | - | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -72,775 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -327,200 | -100.00% | - | Mar 31, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | - | - | - | -3,645 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -74,681 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -2,055,904 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -785,681 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -171,459 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -54,279 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -58,761 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | - | - | - | -83,600 | -100.00% | - | Mar 31, 2024 |
Oncternal Therapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | - | - | - | -20,087 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -35 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -6,417 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -84,706 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -161,401 | -100.00% | - | Mar 31, 2024 |
| VANGUARD GROUP INC | - | - | - | -2,860,906 | -100.00% | - | Mar 31, 2024 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | - | - | - | -53,554 | -100.00% | - | Mar 31, 2024 |
| DELTA ASSET MANAGEMENT LLC/TN | - | - | - | -7 | -100.00% | - | Mar 31, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -32,249 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -92,980 | -100.00% | - | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -72,775 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -327,200 | -100.00% | - | Mar 31, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | - | - | - | -3,645 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -74,681 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -2,055,904 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -785,681 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -171,459 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -54,279 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -58,761 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | - | - | - | -83,600 | -100.00% | - | Mar 31, 2024 |
The largest Oncternal Therapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Oncternal Therapeutics (ONCT), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -1 | -100.00% | - | Mar 31, 2024 |
| CETERA TRUST COMPANY, N.A | - | - | - | -7 | -100.00% | - | Mar 31, 2024 |
| DELTA ASSET MANAGEMENT LLC/TN | - | - | - | -7 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -35 | -100.00% | - | Mar 31, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | - | - | - | -300 | -100.00% | - | Mar 31, 2024 |
| TRUVESTMENTS CAPITAL LLC | - | - | - | -440 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -2,000 | -100.00% | - | Mar 31, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | - | - | - | -3,645 | -100.00% | - | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -4,962 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -6,417 | -100.00% | - | Mar 31, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | - | - | - | -8,850 | -100.00% | - | Mar 31, 2024 |
| XTX TOPCO LTD | - | - | - | -19,505 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -20,087 | -100.00% | - | Mar 31, 2024 |
| IPG INVESTMENT ADVISORS LLC | - | - | - | -23,319 | -100.00% | - | Mar 31, 2024 |
| BETA WEALTH GROUP, INC. | - | - | - | -32,000 | -100.00% | - | Mar 31, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -32,249 | -100.00% | - | Mar 31, 2024 |
| CREATIVE PLANNING | - | - | - | -39,318 | -100.00% | - | Mar 31, 2024 |
| BALBOA WEALTH PARTNERS | - | - | - | -47,500 | -100.00% | - | Mar 31, 2024 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | - | - | - | -53,554 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -54,279 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Oncternal Therapeutics's largest institutional buyer is QUBE RESEARCH & TECHNOLOGIES LTD. The company purchased -1.00 stocks of ONCT, valued at -.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | - | - | - | -2,860,906 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -2,055,904 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -785,681 | -100.00% | - | Mar 31, 2024 |
| PASADENA PRIVATE WEALTH, LLC | - | - | - | -500,000 | -100.00% | - | Mar 31, 2024 |
| RICHMOND BROTHERS, INC. | - | - | - | -494,042 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -327,200 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -171,459 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -161,401 | -100.00% | - | Mar 31, 2024 |
| IEQ CAPITAL, LLC | - | - | - | -144,434 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -92,980 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -84,706 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | - | - | - | -83,600 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -74,681 | -100.00% | - | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -72,775 | -100.00% | - | Mar 31, 2024 |
| AXXCESS WEALTH MANAGEMENT, LLC | - | - | - | -70,363 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -58,761 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -54,279 | -100.00% | - | Mar 31, 2024 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | - | - | - | -53,554 | -100.00% | - | Mar 31, 2024 |
| BALBOA WEALTH PARTNERS | - | - | - | -47,500 | -100.00% | - | Mar 31, 2024 |
| CREATIVE PLANNING | - | - | - | -39,318 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Oncternal Therapeutics's biggest institutional seller is VANGUARD GROUP INC. The company sold -2.86M shares of ONCT, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | - | - | - | -2,860,906 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -2,055,904 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | - | - | - | -785,681 | -100.00% | - | Mar 31, 2024 |
| PASADENA PRIVATE WEALTH, LLC | - | - | - | -500,000 | -100.00% | - | Mar 31, 2024 |
| RICHMOND BROTHERS, INC. | - | - | - | -494,042 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -327,200 | -100.00% | - | Mar 31, 2024 |
| LPL FINANCIAL LLC | - | - | - | -171,459 | -100.00% | - | Mar 31, 2024 |
| STATE STREET CORP | - | - | - | -161,401 | -100.00% | - | Mar 31, 2024 |
| IEQ CAPITAL, LLC | - | - | - | -144,434 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | - | - | - | -92,980 | -100.00% | - | Mar 31, 2024 |
| NORTHERN TRUST CORP | - | - | - | -84,706 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | - | - | - | -83,600 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -74,681 | -100.00% | - | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -72,775 | -100.00% | - | Mar 31, 2024 |
| AXXCESS WEALTH MANAGEMENT, LLC | - | - | - | -70,363 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -58,761 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -54,279 | -100.00% | - | Mar 31, 2024 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | - | - | - | -53,554 | -100.00% | - | Mar 31, 2024 |
| BALBOA WEALTH PARTNERS | - | - | - | -47,500 | -100.00% | - | Mar 31, 2024 |
| CREATIVE PLANNING | - | - | - | -39,318 | -100.00% | - | Mar 31, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -32,249 | -100.00% | - | Mar 31, 2024 |
| BETA WEALTH GROUP, INC. | - | - | - | -32,000 | -100.00% | - | Mar 31, 2024 |
| IPG INVESTMENT ADVISORS LLC | - | - | - | -23,319 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -20,087 | -100.00% | - | Mar 31, 2024 |
| XTX TOPCO LTD | - | - | - | -19,505 | -100.00% | - | Mar 31, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | - | - | - | -8,850 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -6,417 | -100.00% | - | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -4,962 | -100.00% | - | Mar 31, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | - | - | - | -3,645 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -2,000 | -100.00% | - | Mar 31, 2024 |
| TRUVESTMENTS CAPITAL LLC | - | - | - | -440 | -100.00% | - | Mar 31, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | - | - | - | -300 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -35 | -100.00% | - | Mar 31, 2024 |
| DELTA ASSET MANAGEMENT LLC/TN | - | - | - | -7 | -100.00% | - | Mar 31, 2024 |
| CETERA TRUST COMPANY, N.A | - | - | - | -7 | -100.00% | - | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -1 | -100.00% | - | Mar 31, 2024 |
Oncternal Therapeutics's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -2.86M shares, valued at -, as of undefined.
Oncternal Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.06% | 29,166 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 6,739 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 65,934 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 3,402,261 | - | - | Mar 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.01% | 648,370 | - | - | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,312 | - | - | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 31,956 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 447,965 | - | - | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 3,470 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 34,025 | - | - | Mar 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 280,825 | - | - | Jan 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 32,249 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 74,319 | - | - | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 15,983 | - | - | Mar 31, 2024 |
| Meeder Funds | 0.00% | 2,132 | - | - | Mar 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 904 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 139,050 | 139,050 | - | Mar 31, 2024 |
| Global X Funds | 0.00% | 12,682 | - | - | Jan 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,181 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 23,617 | - | - | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 8,600 | - | - | Mar 31, 2024 |
| RBB FUND, INC. | 0.00% | 11,755 | - | - | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 124,096 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 22,580 | 22,580 | - | Feb 29, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 422 | - | - | Dec 31, 2023 |
| FIDELITY SALEM STREET TRUST | 0.00% | 377,842 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 946 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 151,605 | - | - | Feb 29, 2024 |
| PGIM ETF TRUST | 0.00% | 4,726 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,800 | - | - | Mar 28, 2024 |
| Dimensional ETF Trust | 0.00% | 25,892 | 25,892 | - | Jan 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 233 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 16,403 | - | - | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 1,701 | 1,701 | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,235 | - | - | Feb 29, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 4,499 | - | - | Mar 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 5,903 | - | - | Mar 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 263 | - | - | Feb 29, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 1,612 | 1,612 | - | Jan 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 43 | - | - | Dec 31, 2023 |
| TIAA-CREF FUNDS | 0.00% | 103,042 | - | - | Mar 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 4,000 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 6,380 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 5,729 | - | - | Jan 31, 2024 |
| WILSHIRE MUTUAL FUNDS INC | 0.00% | 6,560 | - | - | Dec 31, 2023 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 100 | - | - | Mar 31, 2024 |
| ADVANCED SERIES TRUST | 0.00% | 68,000 | - | - | Mar 28, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,785 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 38,000 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 7 | - | - | Apr 30, 2021 |
| ETF Series Solutions | 0.00% | 288 | - | - | Jan 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 4,880 | - | - | Mar 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 4,778 | - | - | Feb 29, 2024 |
| PACIFIC SELECT FUND | 0.00% | 23,919 | - | - | Mar 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 6,310 | - | - | Jan 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 4,061 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 16,488 | - | - | Mar 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 13 | 13 | - | Feb 29, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 200 | 200 | - | Mar 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 5,279 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 1,095 | - | - | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 94 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 1,813 | - | - | Mar 31, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 57 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 9,500 | - | - | Feb 29, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 2,775 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 2,811 | - | - | Mar 28, 2024 |
Oncternal Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 29.17K shares, compromising 0.06% of its total assets.
Oncternal Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Dec, 23 | 37 | -27.45% |
| 30 Sep, 23 | 51 | -3.77% |
| 30 Jun, 23 | 53 | -1.85% |
| 31 Mar, 23 | 54 | -10.00% |
| 31 Dec, 22 | 60 | 7.14% |
| 30 Sep, 22 | 56 | -20.00% |
| 30 Jun, 22 | 70 | -12.50% |
| 31 Mar, 22 | 80 | -5.88% |
| 31 Dec, 21 | 85 | 4.94% |
| 30 Sep, 21 | 81 | -10.99% |
| 30 Jun, 21 | 91 | 33.82% |
| 31 Mar, 21 | 68 | 21.43% |
| 31 Dec, 20 | 56 | 166.67% |
| 30 Sep, 20 | 21 | 10.53% |
| 30 Jun, 20 | 19 | -5.00% |
| 31 Mar, 20 | 20 | -13.04% |
| 31 Dec, 19 | 23 | 9.52% |
| 30 Sep, 19 | 21 | -8.70% |
| 30 Jun, 19 | 23 | - |
As of 31 Dec 23, 37 institutions are holding Oncternal Therapeutics's shares, representing a decrease of -27.45% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Dec, 23 | 8,387,388 | -10.11% |
| 30 Sep, 23 | 9,330,559 | -1.39% |
| 30 Jun, 23 | 9,462,140 | 1.35% |
| 31 Mar, 23 | 9,336,264 | 5.38% |
| 31 Dec, 22 | 8,859,703 | -5.75% |
| 30 Sep, 22 | 9,400,229 | -14.34% |
| 30 Jun, 22 | 10,974,368 | -18.03% |
| 31 Mar, 22 | 13,388,327 | -0.17% |
| 31 Dec, 21 | 13,411,775 | -1.47% |
| 30 Sep, 21 | 13,612,474 | -0.78% |
| 30 Jun, 21 | 13,720,069 | 39.24% |
| 31 Mar, 21 | 9,853,623 | 17.24% |
| 31 Dec, 20 | 8,404,537 | 99.62% |
| 30 Sep, 20 | 4,210,268 | 55.73% |
| 30 Jun, 20 | 2,703,634 | 97.04% |
| 31 Mar, 20 | 1,372,119 | 8.63% |
| 31 Dec, 19 | 1,263,062 | 12.03% |
| 30 Sep, 19 | 1,127,439 | 289.12% |
| 30 Jun, 19 | 289,742 | - |
Oncternal Therapeutics (ONCT) has 8.39M shares outstanding as of 31 Dec 23, down -10.11% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Dec, 23 | 14.22% | 5.63% |
| 30 Sep, 23 | 15.89% | 6.08% |
| 30 Jun, 23 | 16.17% | 6.35% |
| 31 Mar, 23 | 15.95% | 5.62% |
| 31 Dec, 22 | 16.85% | 5.60% |
| 30 Sep, 22 | 17.34% | 3.61% |
| 30 Jun, 22 | 21.92% | 2.99% |
| 31 Mar, 22 | 27.09% | 3.66% |
| 31 Dec, 21 | 27.19% | 3.58% |
| 30 Sep, 21 | 27.56% | 3.57% |
| 30 Jun, 21 | 27.79% | 6.90% |
| 31 Mar, 21 | 20.07% | 2.46% |
| 31 Dec, 20 | 28.59% | 6.53% |
| 30 Sep, 20 | 20.92% | 7.55% |
| 30 Jun, 20 | 16.65% | 20.85% |
| 31 Mar, 20 | 8.94% | 13.21% |
| 31 Dec, 19 | 8.23% | 15.23% |
| 30 Sep, 19 | 7.35% | 206.01% |
| 30 Jun, 19 | 1.89% | - |
As of 31 Dec 23, Oncternal Therapeutics is held by 14.22% institutional shareholders, representing a 5.63% growth compared to 30 Sep 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Dec, 23 | 10 | -37.50% |
| 30 Sep, 23 | 16 | - |
| 30 Jun, 23 | 16 | 6.67% |
| 31 Mar, 23 | 15 | -40.00% |
| 31 Dec, 22 | 25 | 66.67% |
| 30 Sep, 22 | 15 | -55.88% |
| 30 Jun, 22 | 34 | -8.11% |
| 31 Mar, 22 | 37 | -5.13% |
| 31 Dec, 21 | 39 | - |
| 30 Sep, 21 | 39 | -26.42% |
| 30 Jun, 21 | 53 | 12.77% |
| 31 Mar, 21 | 47 | 4.44% |
| 31 Dec, 20 | 45 | 400.00% |
| 30 Sep, 20 | 9 | 28.57% |
| 30 Jun, 20 | 7 | - |
| 31 Mar, 20 | 7 | -12.50% |
| 31 Dec, 19 | 8 | -38.46% |
| 30 Sep, 19 | 13 | -43.48% |
| 30 Jun, 19 | 23 | - |
10 institutional shareholders have increased their position in ONCT stock as of 31 Dec 23 compared to 16 in the previous quarter (a -37.50% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Dec, 23 | 7 | -22.22% |
| 30 Sep, 23 | 9 | -25.00% |
| 30 Jun, 23 | 12 | - |
| 31 Mar, 23 | 12 | -14.29% |
| 31 Dec, 22 | 14 | -26.32% |
| 30 Sep, 22 | 19 | -9.52% |
| 30 Jun, 22 | 21 | -16.00% |
| 31 Mar, 22 | 25 | -3.85% |
| 31 Dec, 21 | 26 | 18.18% |
| 30 Sep, 21 | 22 | 29.41% |
| 30 Jun, 21 | 17 | 41.67% |
| 31 Mar, 21 | 12 | 300.00% |
| 31 Dec, 20 | 3 | -25.00% |
| 30 Sep, 20 | 4 | - |
| 30 Jun, 20 | 4 | -20.00% |
| 31 Mar, 20 | 5 | -37.50% |
| 31 Dec, 19 | 8 | 60.00% |
| 30 Sep, 19 | 5 | - |
| 30 Jun, 19 | - | - |
7 institutional shareholders have reduced their position in ONCT stock as of 31 Dec 23 compared to 9 in the previous quarter (a -22.22% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Dec, 23 | 37 | -27.45% | 8,387,388 | -10.11% | 14.22% | 5.63% | 10 | -37.50% | 7 | -22.22% |
| 30 Sep, 23 | 51 | -3.77% | 9,330,559 | -1.39% | 15.89% | 6.08% | 16 | - | 9 | -25.00% |
| 30 Jun, 23 | 53 | -1.85% | 9,462,140 | 1.35% | 16.17% | 6.35% | 16 | 6.67% | 12 | - |
| 31 Mar, 23 | 54 | -10.00% | 9,336,264 | 5.38% | 15.95% | 5.62% | 15 | -40.00% | 12 | -14.29% |
| 31 Dec, 22 | 60 | 7.14% | 8,859,703 | -5.75% | 16.85% | 5.60% | 25 | 66.67% | 14 | -26.32% |
| 30 Sep, 22 | 56 | -20.00% | 9,400,229 | -14.34% | 17.34% | 3.61% | 15 | -55.88% | 19 | -9.52% |
| 30 Jun, 22 | 70 | -12.50% | 10,974,368 | -18.03% | 21.92% | 2.99% | 34 | -8.11% | 21 | -16.00% |
| 31 Mar, 22 | 80 | -5.88% | 13,388,327 | -0.17% | 27.09% | 3.66% | 37 | -5.13% | 25 | -3.85% |
| 31 Dec, 21 | 85 | 4.94% | 13,411,775 | -1.47% | 27.19% | 3.58% | 39 | - | 26 | 18.18% |
| 30 Sep, 21 | 81 | -10.99% | 13,612,474 | -0.78% | 27.56% | 3.57% | 39 | -26.42% | 22 | 29.41% |
| 30 Jun, 21 | 91 | 33.82% | 13,720,069 | 39.24% | 27.79% | 6.90% | 53 | 12.77% | 17 | 41.67% |
| 31 Mar, 21 | 68 | 21.43% | 9,853,623 | 17.24% | 20.07% | 2.46% | 47 | 4.44% | 12 | 300.00% |
| 31 Dec, 20 | 56 | 166.67% | 8,404,537 | 99.62% | 28.59% | 6.53% | 45 | 400.00% | 3 | -25.00% |
| 30 Sep, 20 | 21 | 10.53% | 4,210,268 | 55.73% | 20.92% | 7.55% | 9 | 28.57% | 4 | - |
| 30 Jun, 20 | 19 | -5.00% | 2,703,634 | 97.04% | 16.65% | 20.85% | 7 | - | 4 | -20.00% |
| 31 Mar, 20 | 20 | -13.04% | 1,372,119 | 8.63% | 8.94% | 13.21% | 7 | -12.50% | 5 | -37.50% |
| 31 Dec, 19 | 23 | 9.52% | 1,263,062 | 12.03% | 8.23% | 15.23% | 8 | -38.46% | 8 | 60.00% |
| 30 Sep, 19 | 21 | -8.70% | 1,127,439 | 289.12% | 7.35% | 206.01% | 13 | -43.48% | 5 | - |
| 30 Jun, 19 | 23 | - | 289,742 | - | 1.89% | - | 23 | - | - | - |
Oncternal Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Oncternal Therapeutics's stock was made by Wills Robert James on Feb 27 2024, selling 980 shares at $9.04 per share (valued at $8.86K). The last insider buy of ONCT was made by Wills Robert James on Apr 10 2024, buying 3,086 shares at $8.96 per share (worth $27.65K).
Oncternal Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 1 | - | - |
| Q1 2024 | 9 | 7 | 128.57% |
| Q4 2023 | 35 | 30 | 116.67% |
| Q3 2023 | - | 6 | - |
| Q2 2023 | 20 | - | - |
| Q1 2023 | 9 | 8 | 112.50% |
| Q3 2022 | 13 | - | - |
| Q2 2022 | 13 | - | - |
| Q1 2022 | 26 | - | - |
| Q4 2021 | - | - | - |
| Q2 2021 | 10 | 8 | 125.00% |
| Q1 2021 | 9 | - | - |
| Q3 2020 | 7 | 2 | 350.00% |
| Q2 2020 | 10 | 8 | 125.00% |
| Q1 2020 | 9 | 7 | 128.57% |
| Q4 2019 | 1 | 1 | 100.00% |
| Q3 2019 | 16 | 14 | 114.29% |
| Q2 2019 | 23 | - | - |
| Q1 2019 | 2 | - | - |
| Q4 2018 | 3 | - | - |
1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Oncternal Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 1 | - | - |
| Q1 2024 | 3 | 1 | 300.00% |
| Q4 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | 11 | - | - |
| Q1 2023 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | 12 | - | - |
| Q4 2021 | - | - | - |
| Q2 2021 | 1 | 1 | 100.00% |
| Q1 2021 | - | - | - |
| Q3 2020 | 5 | - | - |
| Q2 2020 | 2 | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | - | - | - |
| Q3 2019 | - | - | - |
| Q2 2019 | - | - | - |
| Q1 2019 | - | - | - |
| Q4 2018 | - | - | - |
As of Q2 2024, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Oncternal Therapeutics's stocks.
Oncternal Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| MNPR | Monopar Therapeutics Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| ADTX | Aditxt, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| ABSI | Absci Corporation |
| SRZN | Surrozen, Inc. |
| PASG | Passage Bio, Inc. |
| VCNX | Vaccinex, Inc. |
| ADVM | Adverum Biotechnologies, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| TARA | Protara Therapeutics, Inc. |
| NLTX | Neurogene Inc. |
| KZR | Kezar Life Sciences, Inc. |
| TIL | Instil Bio, Inc. |
ONCT Ownership FAQ
Who Owns Oncternal Therapeutics?
Oncternal Therapeutics is owned by institutional shareholders (14.22%), insiders (9.23%), and public (76.55%). The largest institutional shareholder of Oncternal Therapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.06% of total shares).
Who are the major institutional shareholders of Oncternal Therapeutics?
Oncternal Therapeutics's major institutional shareholders are JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and STATE STREET CORP. The top five shareholders own together 0% of the company's share outstanding.
How many Oncternal Therapeutics shareholders are there?
As of Dec 2023, there are 37 institutional shareholders of Oncternal Therapeutics.
What percentage of Oncternal Therapeutics is owned by JPMORGAN CHASE & CO?
JPMORGAN CHASE & CO owns 0 shares of Oncternal Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).
What percentage of Oncternal Therapeutics is owned by BANK OF AMERICA CORP /DE/?
As of Mar 2024, BANK OF AMERICA CORP /DE/ holds 0 shares of Oncternal Therapeutics (ONCT), compromising 0% of the company, valued at $0.
What percentage of Oncternal Therapeutics is owned by WELLS FARGO & COMPANY/MN?
WELLS FARGO & COMPANY/MN is the third largest holder of Oncternal Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).